



Revision date: 01-Aug-2016 Version: 1.0 Page 1 of 7

IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Precedex (dexmedetomidine hydrochloride) Injection, Solution (Hospira Inc.)

Trade Name: Precedex Not determined **Chemical Family:**

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Sedative/analgesic; alpha-2-adrenergic agonist agent

Details of the Supplier of the Safety Data Sheet Hospira, A Pfizer Company

275 North Field Drive Lake Forest, Illinois 60045

1-800-879-3477

Hospira UK Limited Horizon

Honey Lane Hurley

Maidenhead, SL6 6RJ **United Kingdom**

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards No data available

Note: This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous							
Ingredient	CAS Number	EU	GHS Classification	%			
_		EINECS/ELINCS					
		Lict		1			

Material Name: Precedex (dexmedetomidine hydrochloride) Page 2 of 7

Injection, Solution (Hospira Inc.)

Revision date: 01-Aug-2016 Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS							
Dexmedetomidine hydrochloride	145108-58-3	Not Listed	Muta.2 (H341) Repr.2 (H361d) STOT RE2 (H373)	< 0.1			

Ingredient	CAS Number	EU EINECS/ELINCS	GHS Classification	%
		List		
SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	*
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Formation of toxic gases is possible during heating or fire.

Products:

Fire / Explosion Hazards: Fine particles (such as mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Material Name: Precedex (dexmedetomidine hydrochloride) Page 3 of 7

Injection, Solution (Hospira Inc.)

Revision date: 01-Aug-2016 Version: 1.0

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill Measures for Cleaning /

Collecting: area thoroughly.

Additional Consideration for Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel. Large Spills:

7. HANDLING AND STORAGE

Precautions for Safe Handling

Restrict access to work area. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Dexmedetomidine reported to produce violent reactions with BrF3, H2SO4, KMnO4 Incompatible Materials: Specific end use(s): Pharmaceutical product used as Sedative/analgesic; alpha-2-adrenergic agonist agent

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

SODIUM CHLORIDE

Latvia OEL - TWA 5 mg/m³ Lithuania OEL - TWA 5 mg/m³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Dexmedetomidine hydrochloride

Pfizer Occupational Exposure OEB 5 (control exposure to <1 ug/m³)

Band (OEB):

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Refer to applicable national standards and regulations in the selection and use of personal **Personal Protective**

protective equipment (PPE). **Equipment:**

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug Hands:

product is possible and for bulk processing operations. (Protective gloves must meet the

standards in accordance with EN374, ASTM F1001 or international equivalent.)

Material Name: Precedex (dexmedetomidine hydrochloride) Page 4 of 7

Injection, Solution (Hospira Inc.)

Revision date: 01-Aug-2016 Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Impervious disposable protective clothing is recommended if skin contact with drug product is Skin:

possible and for bulk processing operations. (Protective clothing must meet the standards in

accordance with EN13982, ANSI 103 or international equivalent.)

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is Respiratory protection:

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid Color: Clear, colorless No data available. Odor: **Odor Threshold:** No data available.

Molecular Formula: Mixture **Molecular Weight:** Mixture

No data available **Solvent Solubility:** Water Solubility: No data available No data available. :Ha Melting/Freezing Point (°C): No data available Boiling Point (°C): No data available. Partition Coefficient: (Method, pH, Endpoint, Value)

SODIUM CHLORIDE No data available Water for Injection No data available

Dexmedetomidine hydrochloride

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available Vapor Pressure (kPa): No data available Vapor Density (q/ml): No data available **Relative Density:** No data available Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C): No data available Flammability (Solids): No data available Flash Point (Liquid) (°C): No data available **Upper Explosive Limits (Liquid) (% by Vol.):** No data available Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: Dexmedetomidine reported to produce violent reactions with BrF3, H2SO4, KMnO4

Hazardous Decomposition No data available

Products:

Material Name: Precedex (dexmedetomidine hydrochloride) Page 5 of 7

Injection, Solution (Hospira Inc.)

Revision date: 01-Aug-2016 Version: 1.0

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

Toxicological properties have not been thoroughly investigated. The information in this section

describes the potential hazards of the individual ingredients and the formulation.

Known Clinical Effects:

Based on clinical trials in humans, possible adverse effects following intravenous exposure to this compound may include: decrease in blood pressure (hypotension), increase in blood pressure (hypotension), nausea, decreased heart rate (bradycardia), fever, vomiting, increased heart rate (tachycardia), and decreased red blood cell count (anemia).

Acute Toxicity: (Species, Route, End Point, Dose)

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³ Rat Oral LD 50 3g/kg

Mouse Oral LD 50 4g/kg Rabbit Dermal LD 50 > 10g/kg

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Dexmedetomidine hydrochloride

28 Day(s) Rat Intravenous Eyes, Adrenal gland, Lungs 28 Day(s) Rat Intramuscular Adrenal gland, Eyes, Lungs 28 Day(s) Dog Intravenous Liver, Central Nervous System

28 Day(s) Dog Intramuscular 10 µg/kg/day NOAEL Liver, Central Nervous System

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Dexmedetomidine hydrochloride

Embryo / Fetal Development Rat Subcutaneous 20 ug/kg NOAEL Not teratogenic, Fetotoxicity

Peri-/Postnatal Development Rat Subcutaneous 2 ug/kg/day NOAEL Fetotoxicity, Developmental toxicity

Embryo / Fetal Development Rabbit Intravenous 96 ug/kg/day NOAEL Not Teratogenic

Reproductive & Fertility Rat Subcutaneous 54 ug/kg/day NOAEL Fertility

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Dexmedetomidine hydrochloride

In Vitro Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative In Vitro Mammalian Cell Mutagenicity Mouse Lymphoma Negative

In Vitro Chromosome Aberration Human Lymphocytes Positive with activation, Negative without activation

In Vivo Micronucleus Mouse Positive

Carcinogen Status: Not listed as a carcinogen by IARC, NTP or US OSHA.

PZ02986

Material Name: Precedex (dexmedetomidine hydrochloride) Page 6 of 7

Injection, Solution (Hospira Inc.)

Revision date: 01-Aug-2016 Version: 1.0

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Dexmedetomidine hydrochloride

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed

Not Listed

SODIUM CHLORIDE

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Not Listed

Not Listed

Not Listed

Not Present

Material Name: Precedex (dexmedetomidine hydrochloride) Page 7 of 7

Injection, Solution (Hospira Inc.)

Revision date: 01-Aug-2016 Version: 1.0

15. REGULATORY INFORMATION

Australia (AICS):PresentEU EINECS/ELINCS List231-598-3

Water for Injection

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the obligations of Register:

Not Listed

Not Listed

Not Listed

Not Listed

Present

EU EINECS/ELINCS List 231-791-2

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 01-Aug-2016

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
